metadoxine also known pyridoxinepyrrolidone carboxylate drug used treat chronic acute alcohol metadoxine accelerates alcohol clearance metadoxine ion pair salt pyridoxine pyrrolidone carboxylate pyridoxine vitamin precursor coenzymes including pyridoxal phosphate plp accelerates metabolic degradation ethanol prevents adenosine triphosphate atp inactivation acetaldehyde pyridoxal phosphate dependent enzymes also play role biosynthesis four important neurotransmitters serotonin epinephrine norepinephrine gaba see vitamin functions treatment alcohol intoxication liver disease metadoxine typically given intravenously immediate release formulationcitation needed clinical studies metadoxine reported reduce halflife ethanol healthy volunteers acutely intoxicated patients accelerate metabolism alcohol acetaldehyde less toxic higher ketones improve urinary clearance restore laboratory variables alcohol ammonia γgt alanine aminotransferase improve clinical symptoms alcohol intoxication including psychomotor agitation depression aggressiveness equilibrium also evidence metadoxine effect reducing craving data clinical studies also support effect metadoxine reducing indices liver cell necrosis fat accumulation alcoholic fatty metadoxine may block differentiation step preadipocytes inhibiting creb phosphorylation binding camp response element thereby repressing ccaatenhancerbinding protein b hormoneinduced metadoxine given immediate release form doses mg twice day mg three times day months shown improve biochemical indices liver function well reduce ultrasonic evidence fatty liver metadoxine selective antagonist serotonin receptor subtype displays high affinity gammaaminobutyric acid gaba transporter vitro enzymatic assay revealed metadoxine reduced activity gaba transaminase enzyme responsible degradation gaba electrophysiological studies also showed metadoxine increased inhibitory gabaergic synaptic transmission via presynaptic effect affect dopamine norepinephrine serotonin levels metadoxine displays novel mechanism action monoamineindependent gaba animal studies metadoxine increased activity acetaldehyde dehydrogenase enzyme prevented decrease alcohol dehydrogenase activity chronic ethanolfed rats accelerated plasma urinary clearance ethanol inhibited increase fatty acid esters liver ethanoltreated rats prevented formation fatty liver rats exposed dose ethanol sufficient induce fatty liver increased glutathione levels hepatocytes acutely chronically alcoholintoxicated rats prevented glutathione depletion lipid peroxidation damage collagen deposition tnfα secretions induced alcohol acetaldehyde hepatocytes hepatic stellate metadoxine predominantly used metadoxine immediate release formulation developing nations acute alcohol intoxication chronic alcoholic liver disease alternate names include attention deficit hyperactivity disorder adhd one common neurobehavioral disorders childhood among prevalent chronic health conditions affecting schoolaged children core symptoms adhd include inattention difficulty staying focused hyperactivity metadoxine exhibited cognition enhancing effect rat social recognition animal modelcitation needed extended release formulation metadoxine mdx combining immediate slow release formulations metadoxine single oral dose developed extend halflife drug allow use mdx indications require longer therapeutic window cognitive impairmentrelated disorders mdx demonstrated significant clinically meaningful improvements multiple measures cognition adhd symptoms quality life across multiple studies adults several phase ii adhd studies demonstrated consistent signal efficacy reaching statistical significance measured neuropsychological testing computerized test variables attention tova acute settings clinical scales chronic administration studies treatmentrelated serious adverse events major differences adverse events profiles drug placebo common adverse events nausea fatigue phase study adults adhd completed alcobra ltd conducting phase iii trial announced january drug failed trial failure announcement came week alcobra fda agreement review data collected date measure study consider future nda submission mdx adhd fda also agreed change full clinical hold trial partial clinical hold pending review approval companys proposed protocol phase study assess potential relevance adverse findings observed longterm animal studies metadoxine relation human exposure alcobra fragile x syndrome fxs genetic disorder common single gene cause intellectual disability individuals fxs often number behavioral symptoms including cognitive impairment inattention hyperactivity impulsivity autistic symptoms shyness aggression anxiety hand flapping hand biting high sensitivity autism spectrum disorder seen approximately males females fxs additional fxs individuals display autistic symptoms without autism adhd commonly diagnosed fxs reported occur individuals fxs animal model knockout mouse model metadoxine treatment improved behavioral impairments learning memory social interaction reversed overactivation biomarkers akt extracellular signalregulated kinase erk blood brain juvenile adult mice metadoxine also demonstrated restoration abnormal neuronal morphology well reduced exaggerated basal protein production implicated pathophysiology fxs presumed responsible impaired learning safety efficacy mdx adolescents adults fxs evaluated phase ii study completed httpsenwikipediaorgwikimetadoxine